New antibody therapy takes aim at tough blood cancers
Disease control
Not yet recruiting
This early-phase study tests a new antibody drug, 4A10, in 24 adults with relapsed or hard-to-treat acute lymphoblastic leukemia or lymphoblastic lymphoma. The drug targets a protein on cancer cells to block their growth and help the immune system attack them. The main goals are …
Phase: PHASE1 • Sponsor: Allterum Therapeutics, Inc • Aim: Disease control
Last updated May 26, 2026 11:31 UTC